PeptiDream Inc
TSE:4587
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 226.5
2 984.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
PeptiDream Inc
PeptiDream Inc
Current Portion of Long-Term Debt
PeptiDream Inc
Current Portion of Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Current Portion of Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
PeptiDream Inc
TSE:4587
|
Current Portion of Long-Term Debt
¥2.6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
GNI Group Ltd
TSE:2160
|
Current Portion of Long-Term Debt
¥694m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
51%
|
|
|
Takara Bio Inc
TSE:4974
|
Current Portion of Long-Term Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pharma Foods International Co Ltd
TSE:2929
|
Current Portion of Long-Term Debt
¥676m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
96%
|
|
|
S
|
StemRIM Inc
TSE:4599
|
Current Portion of Long-Term Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
Cuorips Inc
TSE:4894
|
Current Portion of Long-Term Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
PeptiDream Inc
Glance View
PeptiDream Inc., a biopharmaceutical powerhouse based in Japan, has carved out a formidable niche by leveraging its proprietary Peptide Discovery Platform System (PDPS) to revolutionize drug development. Founded in 2006 by a team of visionary scientists, the company has positioned itself at the cutting edge of peptide therapeutics. By using the PDPS, PeptiDream identifies and optimizes macrocyclic peptide candidates that have the potential to address a myriad of complex diseases with unmet medical needs. This platform enables the company to create highly specific peptide-based drugs that can modulate challenging targets previously deemed “undruggable” by conventional methods. For PeptiDream, innovation isn’t just a mission statement but an operational ethos that drives its strategic collaborations and partnerships across the pharmaceutical landscape. Revenue generation at PeptiDream is predominantly through multi-faceted strategic collaborations with leading global pharmaceutical companies. By partnering with industry titans, PeptiDream licenses access to its cutting-edge PDPS technology and collaborates on drug discovery and development projects. This collaborative approach allows the company to secure upfront payments, research funding, milestone payments, and potential royalties on the eventual sales of successfully commercialized drugs. By securing a steady stream of income through these partnerships, PeptiDream not only sustains its robust research and development initiatives but also fuels an innovation pipeline that positions it as a leader in the burgeoning field of peptide-based therapeutics.
See Also
What is PeptiDream Inc's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
2.6B
JPY
Based on the financial report for Sep 30, 2024, PeptiDream Inc's Current Portion of Long-Term Debt amounts to 2.6B JPY.
What is PeptiDream Inc's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 1Y
18%
Over the last year, the Current Portion of Long-Term Debt growth was 18%.
You don't have any saved screeners yet
